Catalysts / TNYA
Upcoming FDA decisions and readouts we track for Tenaya Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Tenaya Therapeutics (TNYA, listed on Nasdaq). They cover 2 programmes: TN-201 (MYBPC3-associated hypertrophic cardiomyopathy) and TN-401 (PKP2-associated arrhythmogenic right ventricular cardiomyopathy).
First on the list: the Phase 1B/2 readout for TN-201 (MYBPC3-associated hypertrophic cardiomyopathy), guided by the company to Q4 2026. By stage, the upcoming rows are 2 Phase 1B/2 readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics TNYA · Nasdaq | TN-201 | MYBPC3-associated hypertrophic cardiomyopathy | Q4 2026 company guidance |
Phase 1B/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Tenaya Therapeutics TNYA · Nasdaq | TN-401 | PKP2-associated arrhythmogenic right ventricular cardiomyopathy | Q4 2026 company guidance |
Phase 1B/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList